What is the dosage of Cyltezo?

Cyltezo is available in 6 dosages, including 50 mg/ml Auto-Injector 0.8 ml, 50 mg/ml Prefilled Syringe 0.2 ml, 50 mg/ml Prefilled Syringe 0.4 ml, 50 mg/ml Prefilled Syringe 0.8 ml, mixed Pack and mixed Pack

What does Cyltezo treat?

Cyltezo treats Juvenile Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Ankylosing Spondylitis, Uveitis, Psoriatic Arthritis and Hidradenitis Suppurativa

What is Cyltezo made of?

Cyltezo contains adalimumab which is a Tumor Necrosis Factor Blocker

How is Cyltezo administered?

Cyltezo is administered as a Injectable or Pack

What is Cyltezo mechanism of action?

Cyltezo mechanism of action is Tumor Necrosis Factor Receptor Blocking Activity

Dosage & Administration Drug label Samples Prior authorization Financial assistance

Patient education People also ask

Cyltezo

(adalimumab-adbm)

CYLTEZO 10 MG in 0.2 ML Prefilled SyringeCYLTEZO 20 MG in 0.4 ML Prefilled Syringe

View 4 more

BOXED WARNING

Dosage & administration

* Administer by subcutaneous injection

Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis :

* Adults: 40 mg every other week.
* Some patients with RA not receiving methotrexate may benefit from increasing the dosage to 40 mg every week or 80 mg every other week.

Juvenile Idiopathic Arthritis :

Pediatric Weight 2 Years of Age and Older	Recommended Dosage
10 kg (22 lbs) to less than 15 kg (33 lbs)	10 mg every other week
15 kg (33 lbs) to less than 30 kg (66 lbs)	20 mg every other week
30 kg (66 lbs) and greater	40 mg every other week

Crohn's Disease :

* Adults: 160 mg on Day 1 (given in one day or split over two consecutive days); 80 mg on Day 15; and 40 mg every other week starting on Day 29.
* Pediatric Patients 6 Years of Age and Older:

Pediatric Weight	Recommended Dosage
Pediatric Weight	Days 1 and 15	Starting on Day 29
17 kg (37 lbs) to less than 40 kg (88 lbs)	Day 1: 80 mg Day 15: 40 mg	20 mg every other week
40 kg (88 lbs) and greater	Day 1: 160 mg (single dose or split over two consecutive days) Day 15: 80 mg	40 mg every other week

Ulcerative Colitis :

* Adults: 160 mg on Day 1 (given in one day or split over two consecutive days), 80 mg on Day 15 and 40 mg every other week starting on Day 29. Discontinue in patients without evidence of clinical remission by eight weeks (Day 57).

Plaque Psoriasis or Adult Uveitis :

* Adults: 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose.

Hidradenitis Suppurativa :

* Adults:
* Day 1: 160 mg (given in one day or split over two consecutive days)
* Day 15: 80 mg
* Day 29 and subsequent doses: 40 mg every week or 80 mg every other week

drug label

Cyltezo prescribing information

Contact Medical Science Liaison Report Adverse Event

prior authorization

Cyltezo prior authorization resources

Coverage Authorization Appeals

Learn More

Benefits investigation

Cyltezo BI Plus Enrollment Form - Rheumatology

Cyltezo BI Plus Enrollment Form - Gastroenterology

Cyltezo BI Plus Enrollment Form - Dermatology

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Cyltezo financial assistance options

Co-pay savings program

commercial only

Enroll in Patient Savings Program

Cyltezo BI Plus Enrollment Form - Rheumatology

Cyltezo BI Plus Enrollment Form - Gastroenterology

Cyltezo BI Plus Enrollment Form - Dermatology

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form